Introduction {#Sec1}
============

Since December 8, 2019, Wuhan, Hubei, China, has reported several cases of COVID-19. In addition to China, other countries including South Korea, Iran, and Italy also have reported cases of COVID-19 infection \[[@CR1], [@CR2]\]. According to the "New Coronavirus Infected Pneumonia Diagnosis and Treatment Plan (Trial Version 5)," during the study period \[[@CR3]\], severe and critically ill patients are at risk for secondary systemic multiple organ failure, which in turn increases the risk of death. Therefore, it is necessary to treat critically ill patients and also prevent mild-moderate cases from developing into severe cases. The mobile cabin hospital has played an important role in stemming China's outbreak of COVID-19 infection, especially in isolating and treating patients diagnosed as mild-moderate disease. However, information about these patient's characteristics and the outcomes are scarce. Although previous studies reported the clinical characteristics of patients with COVID-19 pneumonia \[[@CR4]--[@CR7]\], limited research focused on the patients who developed from mild-moderate to severe disease, our study mainly analyzed the clinical characteristics of these cases admitted to the mobile cabin hospital (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1The flow chart of consultation for patients infected with COVID-19

Results {#Sec2}
=======

Among the cohort of 483 patients, 62 patients (12.8%) progressed to severe cases, and 421 patients (87.2%) were cured. The median age was 50 years, and 54.9% of cases were female. Besides, 61.7% of patients were exposed to the suspected/confirmed patients, and 45.5% of patients experienced family cluster infection. We found increasing odds of severe cases associated with comorbidities, including primary pulmonary disease (7.6% vs. 16.1%, *p* = 0.047), coronary heart disease (0.7% vs. 8.1%, *p* \< 0.001), and abnormal laboratory test of renal (0.2%vs. 16.1%, *p* \< 0.001), liver function (1.9%vs. 19.4%, *p* \< 0.001), renal function (0.2% vs. 16.1%, *p* \< 0.001), heart function (1.2% vs. 19.4%, *p* \< 0.001), and abnormal lymphocyte (15.2% vs. 37.1%, *p* \< 0.001) and leukocyte counts (23.0% vs. 37.1%, *p* = 0.025) (Table [1](#Tab1){ref-type="table"}). By March 9, 2020, all patients were as follows: 62 patients who were diagnosed as severe cases were transferred to a designated hospital for intensive care, of whom, 23 refused (alive confirmed), 8 patients were cured and discharged, and 31 patients were still in the designated hospital to continue treatment and recovered.Table 1Clinical characteristics of patients with coronavirus disease 2019OverallMild-moderate cases (+/++)Severe cases (+++/++++)*p*^a^ value(*n* = 483)(*n* = 421)(*n* = 62)Time from symptom to admission0.585  Mean (SD, min, max)5.86 (5.23, 0.00, 30.0)5.90 (5.27, 0.00, 30.0)5.52 (4.91, 0.00, 18.0)  Median (IQR)4.00 (2.00, 8.00)4.00 (2.00, 8.00)3.00 (2.00, 9.00)Time from admission to cure/severe illness\< 0.001  Mean (SD, min, max)12.2 (4.71, 1.00, 23.0)12.5 (4.51, 1.00, 23.0)9.74 (5.32, 1.00, 23.0)  Median (IQR)12.0 (9.00, 15.0)13.0 (9.00, 16.0)9.00 (5.25, 13.8)Time from symptom to cure/severe illness0.002  Mean (SD, min, max)18.0 (7.41, 1.00, 50.0)18.4 (7.35, 1.00, 50.0)15.3 (7.32, 1.00, 50.0)  Median (IQR)17.0 (13.0, 23.0)17.0 (13.0, 23.0)14.5 (9.25, 21.0)Demographic characteristics0.830  Age    Mean (SD, min, max)48.4 (12.4, 11.0, 83.0)48.5 (12.4, 11.0, 72.0)48.1 (12.9, 22.0, 83.0)    Median (IQR)50.0 (39.0, 58.0)50.0 (39.0, 58.0)48.5 (37.3, 58.8)  Age distribution0.360    (\~ 50\]227 (47.0%)194 (46.1%)33 (53.2%)    (50\~256 (53.0%)227 (53.9%)29 (46.8%)  Sex0.341    Female265 (54.9%)227 (53.9%)38 (61.3%)   Male218 (45.1%)194 (46.1%)24 (38.7%)  BMI0.738    Mean (SD, min, max)23.3 (3.15, 15.0, 37.8)23.3 (3.15, 15.0, 37.8)23.4 (3.15, 16.5, 31.3)    Median (IQR)22.9 (21.4, 25.4)22.9 (21.4, 25.4)23.1 (21.9, 25.5)  BMI distribution0.485    (\~ 18.4\]25 (5.2%)20 (4.8%)5 (8.1%)    (18.5, 23.9\]271 (56.1%)239 (56.8%)32 (51.6%)    (24, 27.9\]155 (32.1%)136 (32.3%)19 (30.6%)    \[28\~)32 (6.6%)26 (6.2%)6 (9.7%)  Huanan seafood wholesale market exposure0.574    No475 (98.3%)413 (98.1%)62 (100%)    Yes8 (1.7%)8 (1.9%)0 (0%)  History suspected patient exposure0.080    Uncertain185 (38.3%)168 (39.9%)17 (27.4%)    Yes298 (61.7%)253 (60.1%)45 (72.6%)  With other family member infected0.011    No263 (54.5%)239 (56.8%)24 (38.7%)    Yes220 (45.5%)182 (43.2%)38 (61.3%)  Daily exercise0.730    No189 (39.1%)163 (38.7%)26 (41.9%)    Yes294 (60.9%)258 (61.3%)36 (58.1%)  Daily self-care ability\< 0.001    No22 (4.6%)8 (1.9%)14 (22.6%)    Yes461 (95.4%)413 (98.1%)48 (77.4%)  Smoking0.063    Current smokers83 (17.2%)66 (15.7%)17 (27.4%)    Give up smoking15 (3.1%)14 (3.3%)1 (1.6%)    Never smokers385 (79.7%)341 (81.0%)44 (71.0%)  Marital status0.782    Divorce3 (0.6%)3 (0.7%)0 (0%)    Married454 (94.0%)395 (93.8%)59 (95.2%)    Unmarried26 (5.4%)23 (5.5%)3 (4.8%)  Recent surgery history\< 0.001    No101 (20.9%)99 (23.5%)2 (3.2%)    Yes382 (79.1%)322 (76.5%)60 (96.8%)  Antiviral drug treatment before admission0.874    No164 (34.0%)144 (34.2%)20 (32.3%)    Yes319 (66.0%)277 (65.8%)42 (67.7%)  Antibiotic drug treatment before admission0.723    No193 (40.0%)170 (40.4%)23 (37.1%)    Yes290 (60.0%)251 (59.6%)39 (62.9%)Comorbidities at admission  Primary pulmonary disease0.047    No441 (91.3%)389 (92.4%)52 (83.9%)    Yes42 (8.7%)32 (7.6%)10 (16.1%)  Hypertension0.067    No449 (93.0%)392 (93.1%)57 (91.9%)    Yes34 (7.0%)29 (6.9%)5 (8.1%)  Diabetes0.072    No459 (95.0%)401 (95.2%)58 (93.5%)    Yes24 (5.0%)20 (4.8%)4 (6.5%)  Hyperlipidemia0.124    No470 (97.3%)412 (97.9%)58 (93.5%)    Yes13 (2.7%)9 (2.1%)4 (6.5%)  Coronary heart disease\< 0.001    No475 (98.3%)418 (99.3%)57 (91.9%)    Yes8 (1.7%)3 (0.7%)5 (8.1%)  History of myocardial infarction0.048    No476 (98.6%)417 (99.0%)59 (95.2%)    Yes7 (1.4%)4 (1.0%)3 (4.8%)  Cerebral infarction0.849    No478 (99.0%)416 (98.8%)62 (100%)    Yes5 (1.0%)5 (1.2%)0 (0%)  Cerebral hemorrhage0.266    No482 (99.8%)420 (99.8%)62 (100%)    Yes1 (0.2%)1 (0.2%)0 (0%)  Malignant neoplasms0.849    No478 (99.0%)416 (98.8%)62 (100%)    Yes5 (1.0%)5 (1.2%)0 (0%)  Other disease0.039    No442 (91.5%)390 (92.6%)52 (83.9%)    Yes41 (8.5%)31 (7.4%)10 (16.1%)Vital signs at admission^b^  Blood pressure0.943    Hight blood pressure34 (7.0%)29 (6.9%)5 (8.1%)    Normal blood pressure449 (93.0%)392 (93.1%)57 (91.9%)  Breath\< 0.001    Breathing faster32 (6.6%)20 (4.8%)12 (19.4%)    Normal breathing451 (93.4%)401 (95.2%)50 (80.6%)  Heart rate\< 0.001    Increased heart rate32 (6.6%)21 (5.0%)11 (17.7%)    Normal heart rate451 (93.4%)400 (95.0%)51 (82.3%)Symptom at admission0.897  Mild45 (9.3%)39 (9.3%)6 (9.7%)  Moderate438 (90.7%)382 (90.7%)56 (90.3%)  Highest temperature0.029    Mean (SD, min, max)37.7 (0.86, 36.0, 40.0)37.7 (0.86, 36.0, 40.0)37.9 (0.89, 36.5, 39.9)    Median (IQR)37.8 (36.9, 38.4)37.7 (36.8, 38.3)37.9 (37.2, 38.6)  Temperature distribution0.195    \< 37.5 °C176 (36.4%)158 (37.5%)18 (29.0%)    37.5--38.0 °C112 (23.2%)97 (23.0%)15 (24.2%)    38.1--39.0 °C137 (28.4%)113 (26.8%)24 (38.7%)\> 39.0 °C58 (12.0%)53 (12.6%)5 (8.1%)  Cough0.524    No204 (42.2%)175 (41.6%)29 (46.8%)    Yes279 (57.8%)246 (58.4%)33 (53.2%)  Shortness of breath0.041    No352 (72.9%)314 (74.6%)38 (61.3%)    Yes131 (27.1%)107 (25.4%)24 (38.7%)  Myalgia0.439    No334 (69.2%)288 (68.4%)46 (74.2%)    Yes149 (30.8%)133 (31.6%)16 (25.8%)  Running nose0.240    No408 (84.5%)352 (83.6%)56 (90.3%)      Yes75 (15.5%)69 (16.4%)6 (9.7%)  Arthralgia0.263    No383 (79.3%)330 (78.4%)53 (85.5%)    Yes100 (20.7%)91 (21.6%)9 (14.5%)  Chest tightness0.288    No365 (75.6%)322 (76.5%)43 (69.4%)    Yes118 (24.4%)99 (23.5%)19 (30.6%)  Nausea or vomiting0.015    No415 (85.9%)355 (84.3%)60 (96.8%)    Yes68 (14.1%)66 (15.7%)2 (3.2%)  Headache0.892    No381 (78.9%)333 (79.1%)48 (77.4%)    Yes102 (21.1%)88 (20.9%)14 (22.6%)  Fatigue0.833    No461 (95.4%)401 (95.2%)60 (96.8%)    Yes22 (4.6%)20 (4.8%)2 (3.2%)  Pharyngalgia0.606    No481 (99.6%)419 (99.5%)62 (100%)    Yes2 (0.4%)2 (0.5%)0 (0%)  Nasal congestion0.606    No481 (99.6%)419 (99.5%)62 (100%)    Yes2 (0.4%)2 (0.5%)0 (0%)  Diarrhea0.012    No447 (92.5%)395 (93.8%)52 (83.9%)    Yes36 (7.5%)26 (6.2%)10 (16.1%)  Chill    No478 (99.0%)417 (99.0%)61 (98.4%)    Yes5 (1.0%)4 (1.0%)1 (1.6%)Laboratory test results at admission ^c^  Leukocyte0.025    Abnormal120 (24.8%)97 (23.0%)23 (37.1%)    Normal363 (75.2%)324 (77.0%)39 (62.9%)  Lymphocyte\< 0.001    Abnormal87 (18.0%)64 (15.2%)23 (37.1%)    Normal396 (82.0%)357 (84.8%)39 (62.9%)  Blood glucose0.374    Abnormal glucose24 (5.0%)19 (4.5%)5 (8.1%)    Normal glucose459 (95.0%)402 (95.5%)57 (91.9%)  Renal function\< 0.001    Normal472 (97.7%)420 (99.8%)52 (83.9%)    Abnormal11 (2.3%)1 (0.2%)10 (16.1%)  Heart function\< 0.001    Normal466 (96.5%)416 (98.8%)50 (80.6%)    Abnormal17 (3.5%)5 (1.2%)12 (19.4%)  Liver function\< 0.001    Normal463 (95.9%)413 (98.1%)50 (80.6%)    Abnormal20 (4.1%)8 (1.9%)12 (19.4%)  Urine infection0.129    No435 (90.1%)383 (91.0%)52 (83.9%)    Yes48 (9.9%)38 (9.0%)10 (16.1%)  Imaging of lung\< 0.001    Normal458 (94.8%)415 (98.6%)43 (69.4%)    Abnormal25 (5.2%)6 (1.4%)19 (30.6%)Mental state before admission^d^0.076  Nervous before admission166 (34.4%)138 (32.8%)28 (45.2%)  Without nervous before admission317 (65.6%)283 (67.2%)34 (54.8%)Sleep quality since diagnosis0.005  Bad123 (25.5%)97 (23.0%)26 (41.9%)  Good20 (4.1%)19 (4.5%)1 (1.6%)  Without influence340 (70.4%)305 (72.4%)35 (56.5%)^a^Data are *n* (%) unless otherwise specified; *p* values demonstrate differences between No conversion to severe and conversion to severe patients. *p* \< 0.05 was considered obviously significant^b^Hypertension, ≥ 140/90 mmHg; breath, 12--20 times/min; heart rate, 60--100 times/min^c^Normal reference value \[1\]: leukocyte: adult, (4.0--10.0) × 10\^9/L; child, (5.0--12.0) × 10\^9/L \[2\]; lymphocyte percentage (Lymph%) 20--40%; lymphocyte absolute value (Lymph \#) 1.1--3.2 × 10\^9 \[3\]; fasting whole blood glucose 3.9\~6.1 mmol/L, 1 h after meal 6.7\~9.4 mmol/L, 2 h after meal ≤ 7.8 mmol/L^d^Heart function: tachycardia (100 beats/min)^e^Liver function: ALT 0--46 U/L; AST 0--46 U/L^f^Urine infection: creatinine (30--110 umol/L)

Discussion {#Sec3}
==========

During the COVID-19 outbreak, the number of confirmed cases has exploded in China. The major challenge is to treat and isolate these patients, as well as reduce severe cases and mortality. The establishment of the mobile cabin hospital has witnessed the classification management effectively. In this study, all patients received a nucleic acid test before admission; after the patients were admitted to the mobile cabin hospital, the treatment was carried out according to the "New Coronavirus Infected Pneumonia Diagnosis and Treatment Plan" \[[@CR3]\]. To our knowlegement, this is the largest retrospective cohort study among mild-moderate cases with COVID-19 infection; the clinical course with respect to mild-moderate and severe cases in Wuchang mobile cabin hospital were analyzed in this study.

Our results showed that there was no significant difference in fever between mild-moderate and severe cases, of whom 421 (87.2%) patients were not admitted to the ICU, and 263 (62.5%) patients were identified as having a fever but progressed to critically ill status, suggesting that there may be individual differences in body temperature monitoring and even in the early concealment of the virus \[[@CR8]\]. Consistent with the transmission route, we also found that critically ill patients were characterized by familial cluster infections, which indirectly confirms that COVID-19 can be transmitted through contact \[[@CR9]--[@CR11]\]. If necessary, appropriate psychological intervention during the admission of a patient may contribute to elevating the patient's condition.

So far, the COVID-19 infection has been managed by controlling the source of infection and cutting off the route of transmission dominates, but no effective treatment has been proposed. For critically ill patients, supportive treatments may continue for some time. According to our study, all the cases in the mobile cabin hospital were community-acquired viral infections; no cases of nosocomial infections were found. This also suggested that the safety isolation measures adopted by patients and medical workers in the mobile cabin hospital can significantly reduce the chance of cross-infection.

Several limitations should be highlighted. First, this was a retrospective study and inherent limitations existed; we tried our best to collect detailed information, but not all laboratory information were collected adequately. Second, 23 patients were lost to follow-up, including 10 of them who also refused our follow-up (for this part, the medical records suggested that they were alive), which enabled a lack of analyzing the outcome of patients after being transferred to designated hospital. These patients who lost to follow-up may have a certain impact on the results, especially deviations and existing biases, so exploring the potential risks associated with the deterioration of patients is infeasible. However, depending on this descriptive study, we found that severe cases were associated with comorbidities. We believe that our study population is representative of mild-moderate cases, especially those who transferred to severe cases, for which provided feasible tactics in management of COVID-19 infection.
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